Australian Operations
Include All CSL Sites

bioCSL partners with Immucor to distribute global market-leading transfusion testing technology

bioCSL partners with Immucor to distribute global market-leading transfusion testing technology

Melbourne, Australia — 21-07-2014

bioCSL today announced that it has commenced distribution of Immucor Corporation’s global market‐leading “Capture®” technology platform and reagents in Australia and New Zealand. Capture® is an advanced antibody detection technology used in the cross‐matching of blood used for transfusion.

Capture® features innovative technology which works differently from the techniques commonly used in Australia. Capture® delivers high levels of specificity, potentially reducing both the need for additional testing and delays for patients awaiting a blood transfusion. Moreover, Capture® has a high degree of sensitivity for detection of clinically significant antibodies, providing confidence and accuracy in pre‐transfusion and prenatal screening.

“These products provide a tremendous enhancement to bioCSL’s immunohaematology portfolio, and will allow us to provide even better service to our customers”, said Dr John Anderson, Senior VP and General Manager of bioCSL. “Immucor’s technology is first‐class, and we’re delighted to be partners with them”.

The Immucor product range consists of more than 200 immunohaematology reagents, automated testing devices and Immucor’s Immulink software, which provides seamless integration of any laboratory network’s immunohaematology results. These products have proven to be successful around the world. Immucor is the leading immunohaematology provider to blood banks in the USA, with its technology used in the screening of over 90% of the North American blood supply. The company is also the market leader in immunohaematology solutions for blood banks in Canada and second in Europe.

“The advances offered by Capture® build on our proud record of helping to maintain Australia and New Zealand’s excellent safety record in blood transfusion over the past 30 years”, said Allen Bollands, Director for bioCSL Immunohaematology. “We are confident that Australian and New Zealand immunohaematology leaders will experience benefits similar to their colleagues around the world”.


Media Contact

Sharon McHale
Senior Director Public Affairs
CSL Limited

Phone: +61 3 9389 1506
Mobile: +61 409 978 314
45 Poplar Rd, Parkville, Australia.

About Immucor
Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centres to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of products for all of its market segments. From a standard line of routine testing and screening products to a comprehensive array of specialty products; from large‐scale to smaller‐volume automated instruments that set the standard in automation; from serological to molecular, plus cutting edge software solutions, Immucor is bringing industry‐leading products to blood bank partners, better ensuring that a safe blood supply reaches all who need it.

About bioCSL Immunohaematology
bioCSL Immunohaematology develops, manufactures and markets in vitro diagnostic products for immunohaematology and snake venom detection. Our core skills include the manufacture of Reagent Red Blood Cells (RRBCs), monoclonal antibodies and the production of reagents and ancillary products for immunohaematology laboratories. bioCSL Immunohaematology works closely with the Australian Commonwealth Government Department of Health and Ageing, National Blood Authority and the Australian Red Cross Blood Service to supply vital RRBCs to Australian transfusion and pathology laboratories.

About bioCSL
bioCSL manufactures, markets and distributes seasonal and pandemic influenza vaccine worldwide. In Australia and New Zealand, bioCSL markets a comprehensive range of vaccines and pharmaceutical products. It also manufactures products of national significance for Australia, including antivenoms and Q‐Fever vaccine, and supplies diagnostic reagents in the Australasia region. bioCSL’s cold‐chain logistics business ensures the integrity of CSL products, as well as those of our customers, as they are safely delivered across Australia.

bioCSL is part of the CSL Group which is headquartered in Melbourne Australia. The CSL Group also includes CSL Behring and CSL Plasma. With major facilities in Australia, Germany, Switzerland and the US, CSL has over 11,000 employees working in 25 countries.

Download this release: 
PDF icon bioCSL partners with Immucor to distribute global market-leading transfusion testing technology (127KB)

LinkedIn Twitter Facebook Google+
© 2019 Seqirus